What is he best known for?
The fields of study he is best known for:
- Cancer
- Internal medicine
- Gene
Antoni Ribas mainly focuses on Melanoma, Internal medicine, Cancer research, Immunology and Vemurafenib.
His biological study spans a wide range of topics, including V600E, Trametinib and Drug resistance.
His studies deal with areas such as Surgery and Oncology as well as Internal medicine.
His Surgery research incorporates elements of Gastroenterology and Hazard ratio.
His Cancer research research also works with subjects such as
- MAPK/ERK pathway which intersects with area such as Receptor tyrosine kinase,
- Signal transduction and related Downregulation and upregulation.
The Immunology study combines topics in areas such as Cancer and Blockade.
His most cited work include:
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation (5698 citations)
- PD-1 blockade induces responses by inhibiting adaptive immune resistance (3368 citations)
- Pembrolizumab versus Ipilimumab in Advanced Melanoma (3250 citations)
What are the main themes of his work throughout his whole career to date?
Antoni Ribas spends much of his time researching Melanoma, Internal medicine, Cancer research, Immunology and Oncology.
His Melanoma research integrates issues from Cancer, MEK inhibitor and Trametinib.
He focuses mostly in the field of Internal medicine, narrowing it down to matters related to Surgery and, in some cases, Gastroenterology and Hazard ratio.
His work focuses on many connections between Cancer research and other disciplines, such as Immune checkpoint, that overlap with his field of interest in Tumor microenvironment.
His work in Immunology tackles topics such as Cytotoxic T cell which are related to areas like CD8.
The concepts of his Oncology study are interwoven with issues in Metastatic melanoma, Phases of clinical research, Adverse effect, Randomized controlled trial and Dacarbazine.
He most often published in these fields:
- Melanoma (44.69%)
- Internal medicine (34.35%)
- Cancer research (33.29%)
What were the highlights of his more recent work (between 2018-2021)?
- Melanoma (44.69%)
- Cancer research (33.29%)
- Internal medicine (34.35%)
In recent papers he was focusing on the following fields of study:
Antoni Ribas focuses on Melanoma, Cancer research, Internal medicine, Oncology and Immunotherapy.
His Melanoma research focuses on Adverse effect and how it connects with Toxicity.
His work deals with themes such as Immune checkpoint, T cell, Immune system and Cancer, which intersect with Cancer research.
His research in Internal medicine tackles topics such as Trametinib which are related to areas like Mutant.
His Oncology study combines topics from a wide range of disciplines, such as Survival analysis, Clinical endpoint, Vemurafenib and Dosing.
His Immunotherapy research is multidisciplinary, relying on both Epitope, Antigen, Computational biology and T-cell receptor.
Between 2018 and 2021, his most popular works were:
- Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma. (278 citations)
- Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study (244 citations)
- Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001. (200 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Gene
His primary areas of study are Melanoma, Internal medicine, Cancer research, Oncology and Dabrafenib.
Particularly relevant to Vemurafenib is his body of work in Melanoma.
His Cancer research research incorporates themes from Agonist, Cancer immunotherapy, Immune system, Immunotherapy and Cell therapy.
His Immune system study incorporates themes from Odds ratio, Cancer, Wnt signaling pathway and MEDLINE.
His work is dedicated to discovering how Oncology, Biomarker are connected with Monoclonal, Carcinoma, Lung cancer and Clinical endpoint and other disciplines.
The Dabrafenib study which covers Trametinib that intersects with Mutant and Regimen.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
